Last reviewed · How we verify

Lower albumin dosage

Centro Medico Issemym · Phase 3 active Small molecule

Lower albumin dosage is a Plasma protein / Volume expander Small molecule drug developed by Centro Medico Issemym. It is currently in Phase 3 development for Hypovolemia or plasma volume expansion in critical illness or surgery, Hypoalbuminemia in liver disease or malnutrition. Also known as: Lung ultrasound guided administration of albumin.

Lower albumin dosage reduces the amount of human serum albumin administered to patients, potentially minimizing exposure-related adverse effects while maintaining therapeutic benefit.

Lower albumin dosage reduces the amount of human serum albumin administered to patients, potentially minimizing exposure-related adverse effects while maintaining therapeutic benefit. Used for Hypovolemia or plasma volume expansion in critical illness or surgery, Hypoalbuminemia in liver disease or malnutrition.

At a glance

Generic nameLower albumin dosage
Also known asLung ultrasound guided administration of albumin
SponsorCentro Medico Issemym
Drug classPlasma protein / Volume expander
ModalitySmall molecule
Therapeutic areaCritical Care / Supportive Care
PhasePhase 3

Mechanism of action

Albumin is a carrier protein used clinically for volume expansion, nutritional support, and drug delivery. Reducing the dosage lowers the total protein load administered intravenously, which may decrease the risk of hypervolemia, allergic reactions, and other albumin-related complications. This approach aims to optimize the risk-benefit profile in conditions where albumin therapy is indicated but high doses may be problematic.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Lower albumin dosage

What is Lower albumin dosage?

Lower albumin dosage is a Plasma protein / Volume expander drug developed by Centro Medico Issemym, indicated for Hypovolemia or plasma volume expansion in critical illness or surgery, Hypoalbuminemia in liver disease or malnutrition.

How does Lower albumin dosage work?

Lower albumin dosage reduces the amount of human serum albumin administered to patients, potentially minimizing exposure-related adverse effects while maintaining therapeutic benefit.

What is Lower albumin dosage used for?

Lower albumin dosage is indicated for Hypovolemia or plasma volume expansion in critical illness or surgery, Hypoalbuminemia in liver disease or malnutrition.

Who makes Lower albumin dosage?

Lower albumin dosage is developed by Centro Medico Issemym (see full Centro Medico Issemym pipeline at /company/centro-medico-issemym).

Is Lower albumin dosage also known as anything else?

Lower albumin dosage is also known as Lung ultrasound guided administration of albumin.

What drug class is Lower albumin dosage in?

Lower albumin dosage belongs to the Plasma protein / Volume expander class. See all Plasma protein / Volume expander drugs at /class/plasma-protein-volume-expander.

What development phase is Lower albumin dosage in?

Lower albumin dosage is in Phase 3.

What are the side effects of Lower albumin dosage?

Common side effects of Lower albumin dosage include Hypervolemia / fluid overload, Allergic reaction, Fever, Chills.

Related